GlassScriptPhysician profile
Lawrence M Stokar
NPI 1811998875
$173,547.07
in general payments reported to CMS, 2019-2025
42 companies · $4,211 in 2025
The $4,211 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $39K · 2021: $23K · 2022: $20K · 2023: $8,427 · 2024: $4,776 · 2025: $4,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,800 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,512.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,800.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $103,585.06 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $36,418.10 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $18,518.68 | 2019-2025 | |
| Journey Medical Corporation | $2,482.80 | 2019-2025 | |
| Ucb, INC. | $1,530.86 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $1,451.88 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $1,297.71 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $1,164.03 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $833.81 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Incyte Corporation | $738.31 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $663.19 | 2019-2025 | |
| Lilly USA, LLC | $582.59 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $549.13 | 2019-2025 | Dupixent, Libtayo |
| Aclaris Therapeutics, INC. | $538.39 | 2019 | |
| Genzyme Corporation | $510.65 | 2019-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Stokar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.